Generalized Anxiety Disorders (GAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Report Summary

GlobalData, the industry analysis specialist, has released its new report, “Generalized Anxiety Disorders (GAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Generalized Anxiety Disorders (GAD) Therapeutics market. The report identifies the key trends shaping and driving the global Generalized Anxiety Disorders (GAD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Generalized Anxiety Disorders (GAD) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Generalized Anxiety Disorders (GAD) Therapeutics market. Its scope includes:

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Generalized Anxiety Disorders (GAD) Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Generalized Anxiety Disorders (GAD) Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Generalized Anxiety Disorders (GAD) Therapeutics market.
• Analysis of key recent licensing and partnership agreements in Generalized Anxiety Disorders (GAD) Therapeutics market

Reasons to Buy

    The report will enhance your decision making capability. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Generalized Anxiety Disorders (GAD) Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Generalized Anxiety Disorders (GAD) Therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global Generalized Anxiety Disorders (GAD) Therapeutics market landscape? – Identify, understand and capitalize.

Table of Contents

1 Table of contents

2 Executive Summary

3 Introduction
3.1 Overview
3.2 Epidemiology
3.3 Etiology
3.4 Symptoms
3.5 Diagnosis
3.6 Pathology
3.7 Treatment and Management Pattern
3.8 Referral Pathway

4 Market Characterization
4.1 Major Markets, Market Size (2005-2010)
4.2 Major Markets, Market Forecast (2010-2018)
4.3 US Market Size (2005-2010)
4.4 US Market Forecast (2010-2018)
4.5 France Market Size (2005-2010)
4.6 France Market Forecast (2010-2018)
4.7 Germany Market Size (2005-2010)
4.8 Germany Market Forecast (2010-2018)
4.9 Italy Market Size (2005-2010)
4.1 Italy Market Forecast (2010-2018)
4.11 Spain Market Size (2005-2010)
4.12 Spain Market Forecast (2010-2018)
4.13 UK Market Size (2005-2010)
4.14 UK Market Forecast (2010-2018)
4.15 Japan Market Size (2005-2010)
4.16 Japan Market Forecast (2010-2018)
4.17 Drivers and Barriers
4.18 Opportunity & Unmet Need Analysis
4.19 Key Takeaway

5 Competitive Assessment
5.1 Overview
5.1.1 Strategic Competitor Assessment
5.2 Marketed Product Profiles
5.2.1 Marketed Drug 1
5.2.1.1 Overview
5.2.1.2 Efficacy
5.2.1.3 Safety
5.2.1.4 Clinical Study Details
5.2.1.5 Annual Cost of Therapy
5.2.1.6 Historical Sales
5.3 Key Takeaway

6 Pipeline Assessment
6.1 Overview
6.2 Strategic Pipeline Assessment
6.3 Pipeline Analysis by Phase of Development
6.3.1 Phase III Clinical Pipeline
6.3.2 Phase II Clinical Pipeline
6.3.3 Phase I Clinical Pipeline
6.3.4 Pre-clinical & Discovery Phase
6.4 Pipeline by Mechanism of Action
6.5 Technology Trends Analytical Framework
6.6 Clinical Pipeline by Mechanism of Action, and by Monotherapy & Combination therapy
6.7 Most Promising Drugs under Clinical Development
6.8 Most Promising Drug Profiles
6.8.1 Pipeline Drug 1
6.81.1 Overview
6.8.1.2 Efficacy
6.8.1.3 Safety
6.8.1.4 Clinical Study Details
6.9 Key Takeaway

7 Clinical Trials Mapping
7.1 Clinical Trials by Region/Country
7.2 Clinical Trials by Phase
7.3 Clinical Trials by Trial Status
7.4 Prominent Sponsors
7.5 Top Ten Companies Participating in Therapeutics Clinical Trials

8 Strategic Assessment
8.1 Key Events Impacting the Future Market
8.2 Future Market Competition Scenario

9 Future Players
9.1 Introduction
9.2 Company Profiles
9.2.1 Profiling of top 10 companies among late stage pipeline including deal, alliance and partnerships
9.2.3 Tabular presentation details of other companies in the pipeline
9.3 Key Takeaway

10 Licensing & Partnership Deals

11 Appendix